Management of Symptomatic Uncomplicated Diverticular Disease: A Retrospective Observational Study from Diagnosis to Treatment

Le résumé fourni par la source

Symptomatic uncomplicated diverticular disease (SUDD) currently lacks a fully established treatment consensus, while nutraceuticals are emerging as promising strategies to support patients.A retrospective observational study was conducted to investigate real-world diagnostic and therapeutic approaches to SUDD management.The study assessed whether a nutraceutical synbiotic supplement -containing Lactobacillus rhamnosus GG, Hericium erinaceus, berberine, quercetin, palmitoylethanolamide, and Undaria -could improve stool consistency (Bristol Stool Chart, BSC), abdominal pain intensity (Visual Analogue Scale, VAS), and fecal calprotectin levels.Data were collected at baseline (T0), one month (T1), and 2 months (T2).Colonoscopy was the most frequent diagnostic method (73.2%), followed by abdominal CT (11.6%).At T0, 57.1% of patients were not receiving pharmacotherapy; rifaximin (18.8%) and mesalazine (9.4% alone or combined) were most commonly prescribed agents.Pharmacological treatment declined at T2 (80.4% drug-free), with persistent mesalazine use (7.1%).A significant time-dependent improvement in BSC scores was observed in both constipated and diarrheic patients (p<0.001), with stool normalization achieved in 75% of patients at T2.VAS scores decreased progressively across the entire study population (p<0.001),independently of pharmacological treatment.Fecal calprotectin levels decreased significantly (p<0.001), with more patients achieving negative results.Its baseline correlation with VAS (p<0.001) disappeared at T2.These findings suggest that synbiotic anti-inflammatory supplements may support gut function, relieve pain, and normalize stool patterns in SUDD.Controlled clinical trials are warranted to confirm these preliminary outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.